SEC Form 4 · accession 0000919574-15-004657
Asterias Biotherapeutics, Inc. · AST
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
May 21, 2015
Accepted (ET)
May 26, 2015 · 5:47 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001572552
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Series A Common StockF5,F1 | May 21, 2015 | X | 1,000,000 | $2.34 | A | 1,641,025 | D | |
| Series A Common StockF2 | May 21, 2015 | X | 0 | $0.00 | A | 1,641,025 | I | Footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Warrant to Purchase Series A Common StockF4,F1,F3 | $2.34 | May 21, 2015 | X | 1,000,000 | D | — | Jun 15, 2015 | Series A Common Stock | 1,000,000 | 0 | D |
| Warrant to Purchase Series A Common StockF4,F2,F3 | $2.34 | May 21, 2015 | X | 0 | D | — | Jun 15, 2015 | Series A Common Stock | 0 | 0 | I |
Explanation of responses
- F1These securities are owned by Broadwood Partners, L.P., which is a Reporting Person.
- F2The reported securities are directly owned by Broadwood Partners, L.P. and may be deemed beneficially owned by Broadwood Capital, Inc. as General Partner of Broadwood Partners, L.P. and Neal C. Bradsher as President of Broadwood Capital, Inc. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
- F3These warrants are currently exercisable with the underlying common shares issuable 61 days following the exercise date.
- F4On June 16, 2014, Asterias Biotherapeutics, Inc. (the "Issuer") sold common shares of BioTime, Inc. to Broadwood Partners, L.P. pursuant to a stock purchase agreement. As part of that transaction, these warrants were granted to Broadwood Partners, L.P. under a warrant agreement between the Issuer and Broadwood Partners, L.P.
- F5Reflects the exercise of Series A common stock warrants for 1,000,000 Series A common shares by Broadwood Partners, L.P.
Remarks
Richard LeBuhn, Senior Vice President of Broadwood Capital, Inc., is a Director of the Issuer.